| Dr Paul T Harrington, MD | |
|
2020 Oakley Seaver Dr, Suite 1, Clermont, FL 34711-1902 | |
| (352) 404-7718 | |
| (352) 404-7723 |
| Full Name | Dr Paul T Harrington |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 48 Years |
| Location | 2020 Oakley Seaver Dr, Clermont, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144255720 | NPI | - | NPPES |
| 140682001 | Medicaid | AR | |
| 440002975 | Other | RR MEDICARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Better@home | Clermont, FL | Home health agency |
| South Lake Home Health | Clermont, FL | Home health agency |
| Orlando Health South Lake Hospital | Clermont, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nautilus Health Care Group Llc | 5991604852 | 44 |
News Archive
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.
For type 2 diabetics who are not on insulin, monitoring their blood sugar does little to control blood sugar levels over time and may not be worth the effort or expense, according to a new evidence review.
Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of QuadraMed Corp. arising from the Company's announcement of its intent to be acquired by Francisco Partners.
The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.
AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
› Verified 1 days ago
| Entity Name | Nautilus Health Care Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912013558 PECOS PAC ID: 5991604852 Enrollment ID: O20040108000803 |
News Archive
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.
For type 2 diabetics who are not on insulin, monitoring their blood sugar does little to control blood sugar levels over time and may not be worth the effort or expense, according to a new evidence review.
Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of QuadraMed Corp. arising from the Company's announcement of its intent to be acquired by Francisco Partners.
The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.
AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul T Harrington, MD Po Box 919023, Orlando, FL 32891-9023 Ph: (352) 404-7718 | Dr Paul T Harrington, MD 2020 Oakley Seaver Dr, Suite 1, Clermont, FL 34711-1902 Ph: (352) 404-7718 |
News Archive
Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its drug candidate, SPX-106, achieved statistically significant reductions in triglycerides and cholesterol when administered in combination with D-tagatose for nine weeks to genetically engineered mice prone to dyslipidemia.
For type 2 diabetics who are not on insulin, monitoring their blood sugar does little to control blood sugar levels over time and may not be worth the effort or expense, according to a new evidence review.
Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of QuadraMed Corp. arising from the Company's announcement of its intent to be acquired by Francisco Partners.
The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.
AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
› Verified 1 days ago
Dr. April Louise Oxford, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1900 Don Wickham Dr, Clermont, FL 34711 Phone: 352-536-8840 Fax: 352-536-8841 | |
Rupinder Preet Kaur, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1900 Don Wickham Dr, Clermont, FL 34711 Phone: 352-536-8840 Fax: 352-536-8841 | |
Sung Woong Park, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1900 Don Wickham Dr, Clermont, FL 34711 Phone: 525-368-8303 Fax: 352-236-8841 | |
Dr. Alejandro A Victoria, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 235 Hatteras Avenue, Suite 100, Clermont, FL 34711 Phone: 352-242-0676 Fax: 352-242-1335 | |
Dr. Gopal R. Kunta, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2737 Citrus Tower Blvd, Clermont, FL 34711 Phone: 352-242-1366 | |
Dr. Kerry-anne Sherie Machado, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1900 Don Wickham Dr, Clermont, FL 34711 Phone: 352-536-8840 | |
Mitchell Milstein, Infectious Disease Medicare: Medicare Enrolled Practice Location: 1900 Don Wickham Dr, Clermont, FL 34711 Phone: 352-536-8840 Fax: 352-536-8841 |